Rising prostate-specific antigen after primary prostate cancer therapy (Q36395149)

13 August 2017

1 reference

title

Rising prostate-specific antigen after primary prostate cancer therapy (English)

1 reference

13 August 2017

1 reference

John F Ward

1

1 reference

13 August 2017

Judd W Moul

series ordinal

2

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 April 2005

1 reference

13 August 2017

published in

Nature Reviews Urology

1 reference

13 August 2017

volume

2

1 reference

13 August 2017

issue

4

1 reference

13 August 2017

page(s)

174-182

1 reference

PSA progression following radical prostatectomy and radiation therapy: new standards in the new Millennium

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

Prostate specific antigen: a decade of discovery--what we have learned and where we are going

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

Natural history of progression after PSA elevation following radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

Definitions of biochemical failure in prostate cancer following radiation therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

Salvage radiotherapy for rising or persistent PSA after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

Salvage surgery for radiorecurrent prostate cancer: contemporary outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

Predictors for maximal outcome in patients undergoing salvage surgery for radio-recurrent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

Salvage radical prostatectomy: outcome measured by serum prostate specific antigen levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

Treatment of organ confined prostate cancer with third generation cryosurgery: preliminary multicenter experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

Safety and efficacy of transurethral resection of the prostate under sedoanalgesia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

Choice of hormonal therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: updated results of a multicentric trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

A five-alpha reductase inhibitor or an antiandrogen prevents the progression of microscopic prostate carcinoma to macroscopic carcinoma in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

7 January 2021

The Long-Term Clinical Impact of Biochemical Recurrence of Prostate Cancer 5 or More Years After Radical Prostatectomy

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

7 January 2021

Prostate-specific antigen doubling times in patients who have failed radical prostatectomy: correlation with histologic characteristics of the primary cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

7 January 2021

Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

7 January 2021

Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

7 January 2021

Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: the first 10 years

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

7 January 2021

Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

7 January 2021

Salvage radiotherapy after radical prostatectomy for prostate adenocarcinoma: analysis of efficacy and prognostic factors

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

7 January 2021

Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

7 January 2021

Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radi

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

7 January 2021

Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

7 January 2021

Routine prostate biopsies following radiotherapy for prostate cancer: results for 226 patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

7 January 2021

Androgen deprivation with salvage surgery for radiorecurrent prostate cancer: results at 5-year followup

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

7 January 2021

Morbidity and functional outcomes of salvage radical prostatectomy for locally recurrent prostate cancer after radiation therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

7 January 2021

Introduction. Recent scientific and technological advances have challenged the traditional treatment options for patients with localized prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

7 January 2021

Cryosurgery for prostate cancer: new technology and indications

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

7 January 2021

Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

7 January 2021

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

7 January 2021

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

7 January 2021

Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

7 January 2021

Endocrine profiles during administration of the new non‐steroidal anti‐androgen Casodex in prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

7 January 2021

Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

7 January 2021

The non-steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

7 January 2021

Is there a role for antiandrogen monotherapy in patients with metastatic prostate cancer?

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

7 January 2021

A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

7 January 2021

BICALUTAMIDE MONOTHERAPY COMPARED WITH CASTRATION IN PATIENTS WITH NONMETASTATIC LOCALLY ADVANCED PROSTATE CANCER: 6.3 YEARS OF FOLLOWUP

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

7 January 2021

The bicalutamide Early Prostate Cancer Program. Demography

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

7 January 2021

Bicalutamide as Immediate Therapy Either Alone or as Adjuvant to Standard Care of Patients with Localized or Locally Advanced Prostate Cancer: First Analysis of the Early Prostate Cancer Program

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

7 January 2021

Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

7 January 2021

Treatment with finasteride following radical prostatectomy for prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

7 January 2021

Combination finasteride and flutamide in advanced carcinoma of the prostate: effective therapy with minimal side effects

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

7 January 2021

Combined finasteride and flutamide therapy in men with advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

7 January 2021

Combined treatment of Dunning R3327 rat prostatic tumor with the 5alpha-reductase inhibitor PNU 157706 and the antiandrogen bicalutamide

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

7 January 2021

Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0145

7 January 2021

Identifiers

DOI

10.1038/NCPURO0145

1 reference

Dimensions Publication ID

13 August 2017

1005469264

0 references

1 reference